ABSTRACT
Prostate-specific antigen (PSA) is the most commonly used tumour marker for prostate cancer, both in screening and in follow-up. However, there are many false positive increases in the presence of other prostate diseases and, currently, there is no consensus regarding sensitivity and specificity of the PSA test, nor what constitutes the upper limit of normality. We report a case of a 67-year-old patient with metastatic prostate cancer who, with increased level of alkaline phosphatase and normal PSA, showed clinical and radiological evidence of progression of the disease.
Subject(s)
Adenocarcinoma/blood , Bone Neoplasms/secondary , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Aged , Antineoplastic Agents/therapeutic use , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/drug therapy , Humans , Male , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Radionuclide Imaging , Treatment OutcomeABSTRACT
Prostate-specific antigen (PSA) is the most commonly used tumour marker for prostate cancer, both in screening and in follow-up. However, there are many false positive increases in the presence of other prostate diseases and, currently, there is no consensus regarding sensitivity and specificity of the PSA test, nor what constitutes the upper limit of normality. We report a case of a 67-year-old patient with metastatic prostate cancer who, with increased level of alkaline phosphatase and normal PSA, showed clinical and radiological evidence of progression of the disease
Subject(s)
Male , Aged , Humans , Prostate-Specific Antigen/analysis , Prostatic Neoplasms/secondary , Sensitivity and Specificity , False Negative Reactions , Prostatic Neoplasms/pathology , Neoplasm Metastasis/pathologyABSTRACT
No disponible
No disponible
